Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week

https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-Presents-Positive-Final-Data-from-STARS-Nutrition-a-Phase-II-Study-of-Apraglutide-in-Short-Bowel-Syndrome-with-Intestinal-Failure-SBS-IF-and-Colon-in-Continuity-CIC-at-United-European-Gastroenterology-Week/default.aspx

Ironwood has successfully completed the tender offer of VectivBio, a global clinical-stage biotechnology company
pioneering novel, transformational treatments for severe rare gastrointestinal conditions. For more information, click here